A one-time treatment with monoclonal antibodies reduces hospitalization by as much as 70% to 80% for those exposed to or infected by the virus, says a UNC Health expert.UNC Health, Monday, November 1st, 2021
For many months after the COVID-19 pandemic began, there was no specific treatment for those who had become sick with the virus that has ravaged the world and changed nearly every aspect of daily living. Now, three monoclonal antibody therapies have been granted emergency use authorization by the Food and Drug Administration as a treatment for people with COVID-19 who are not hospitalized.
“In clinical studies of outpatients with COVID-19, a one-time treatment with monoclonal antibodies reduced hospitalization by as much as 70% to 80%,” says UNC Health infectious diseases specialist Dr. David A. Wohl.
UNC Health asked Wohl to explain what exactly are monoclonal antibodies and how they are helping those diagnosed or exposed to COVID-19.